Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack

Background The aim of this study was to analyze the benefits and safety associated with the combination therapy of clopidogrel and aspirin among minor stroke or transient ischemic attack patients treated within 12 hours. Methods and Results This was a subanalysis of the CHANCE (Clopidogrel in High‐Risk Patients with Acute Nondisabling Cerebrovascular Events) trial, mainly limited to the prespecified group of patients randomized within 12 hours to either the combination of clopidogrel plus aspirin or aspirin alone. The primary outcome was ischemic stroke during 90‐day follow‐up. Recurrent ischemic stroke and progressive ischemic stroke were analyzed. Multivariable Cox modeling showed that randomization within 12 hours was an independent predictor of ischemic stroke events (hazard ratio [95% CI] 1.25 [1.04–1.49], P=0.02). Among 2573 patients randomized within 12 hours, 282 (10.96%) patients had ischemic stroke events. Among them, 158 (12.34%) of 1280 patients taking aspirin experienced ischemic stroke compared with 124 (9.59%) of 1293 patients taking clopidogrel–aspirin (P=0.02). The dual antiplatelet was more effective than aspirin alone in reducing the risk of recurrent ischemic stroke (6.57% versus 8.91%, P=0.03) but not progressive ischemic stroke (3.02% versus 3.43%, P=0.28). There was no significant difference in hemorrhagic events (P=0.39). Conclusions Among patients treated within 12 hours, the combination of clopidogrel and aspirin was more effective than aspirin alone in reducing the risk of recurrent ischemic stroke during the 90‐day follow‐up and did not increase the hemorrhagic risk. Clinical Trial Registration URL: https://www.clinicaltrials.gov/. Unique identifier: NCT00979589.

[1]  Albert Trinh-Duc,et al.  Letter by Trinh-Duc et al Regarding Article, "2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association". , 2018, Stroke.

[2]  Yilong Wang,et al.  Prevalence and Outcomes of Symptomatic Intracranial Large Artery Stenoses and Occlusions in China: The Chinese Intracranial Atherosclerosis (CICAS) Study , 2014, Stroke.

[3]  Y. Wang,et al.  Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack , 2013 .

[4]  David Wang,et al.  Consensus Statement on the Use of Intravenous Recombinant Tissue Plasminogen Activator to Treat Acute Ischemic Stroke by the Chinese Stroke Therapy Expert Panel , 2013, CNS neuroscience & therapeutics.

[5]  R. Conwit,et al.  Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: Rationale and design , 2013, International journal of stroke : official journal of the International Stroke Society.

[6]  M. Horton.  Abstract WP56: Refinement of imaging predictors of recurrent events following Transient Ischemic Attack and Minor Stroke. , 2013 .

[7]  S. Johnston,et al.  Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. , 2010, American heart journal.

[8]  K. Tan,et al.  Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial , 2010, The Lancet Neurology.

[9]  M. Kaste.  Time matters for reducing risk of stroke , 2010, The Lancet Neurology.

[10]  A. Demchuk,et al.  Recurrent Events in Transient Ischemic Attack and Minor Stroke: What Events Are Happening and to Which Patients? , 2008, Stroke.

[11]  A. Demchuk,et al.  Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial , 2007, The Lancet Neurology.

[12]  P. Touboul,et al.  A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects , 2007, The Lancet Neurology.

[13]  S Claiborne Johnston,et al.  Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack , 2007, The Lancet.

[14]  M. Correia,et al.  Transient Ischemic Attacks in Rural and Urban Northern Portugal: Incidence and Short-Term Prognosis , 2006, Stroke.

[15]  E. Ringelstein,et al.  Dual Antiplatelet Therapy With Clopidogrel and Aspirin in Symptomatic Carotid Stenosis Evaluated Using Doppler Embolic Signal Detection: The Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) Trial , 2005, Circulation.

[16]  P. Rothwell,et al.  Timing of TIAs preceding stroke , 2005, Neurology.

[17]  H. Diener,et al.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[18]  J. Tu,et al.  The high risk of stroke immediately after transient ischemic attack , 2004, Neurology.

[19]  S. Sidney,et al.  Short-term prognosis after emergency department diagnosis of TIA. , 2000, JAMA.

[20]  V. Fuster,et al.  Acute Antithrombotic Effect of a Front-Loaded Regimen of Clopidogrel in Patients With Atherosclerosis on Aspirin , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[21]  R. Sacco,et al.  The stroke prognosis instrument II (SPI-II) : A clinical prediction instrument for patients with transient ischemia and nondisabling ischemic stroke. , 2000, Stroke.

[22]  G. D. del Zoppo.  The role of platelets in ischemic stroke , 1998, Neurology.

[23]  G. Zoppo.  The role of platelets in ischemic stroke , 1998 .

[24]  Zheng-Ming Chen,et al.  CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke , 1997, The Lancet.

[25]  Peter Sandercock,et al.  The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.

[26]  A. Rabinstein.  Addition of brain and carotid imaging to the ABCD2 score to identify patients at early risk of stroke after transient ischaemic attack: a multicentre observational study , 2011 .

[27]  P. Rothwell,et al.  Validation and refi nement of scores to predict very early stroke risk after transient ischaemic attack , 2007 .

[28]  Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. , 1998, JAMA.

[29]  The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. , 1997, Lancet.

[30]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.